Latest research on MK-0518

Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. [Wikipedia]

Latest findings

The availability of ARV drugs began in 1987 with the zidovidine and the latest ones to be approved in 2007 are the Maraviroc [8] and Raltegravir [9] potassium marketed as Selzentry (Pfizer) and Isentress (Merck) respectively. [source, 2010]
IN inhibitors raltegravir (RAL or MK-0518) and L-000870812 [15] were also evaluated for their ability to inhibit XMRV in the two cell systems (Figure 1, Figure 2 C and D). [source, 2010]
Furthermore, in June 2009, Isentress received an extended indication for previously untreated patients, in combination with standard treatment. [source, 2009]
One of the first integrase inhibitors to be developed is raltegravir (MK-0518). [source, 2009]
RAL (or MK-0518) is a member of the INSTI family. [source, 2009]
Raltegravir (MK-0518) is clinically used against viruses resistant to other antiretroviral compounds. [source, 2009]